18 Jan Luminary Therapeutics
Jeff Liter, President and CEO
April 13 | 11:00am | Dark Horse Consulting Ballroom
Luminary is a clinical-stage CAR-T therapy company with a novel allogeneic manufacturing platform where our CAR and TCR development utilizes gamma delta cells. What makes our allogeneic therapeutics unique are that our final drug product includes the combinatory power of both the Vẟ1 and Vẟ2 gamma delta cells, giving our therapies the power of both innate and adaptive cancer clearing power. We have multiple solid tumor targets under development with a proprietary signaling method to ensure T cell persistence. Additionally, our Ligand BAFF CAR for hematologic cancers is designed with three antigen receptors specifically designed to overcome antigen escape.